Biogen ( NASDAQ: BIIB) said on Wednesday that the U.S. FDA has granted Fast Track designation to BIIB080, its antisense ...

Ionis has entered a licence agreement with Sobi in which the latter obtains exclusive rights to commercialise olezarsen.

NewSound, a leading innovator in hearing aids with over two decades of expertise, today launched its first truly AI-driven over-the-counter hearing aid, powered by Femtosense's AI Acceleration.

Garmin Ltd. invites shareholders and investors to listen to its first quarter 2025 earnings conference call on Wednesday, April 30, 2025, at 10:30 a.m. EDT, with executives of Garmin. The call will be ...

Ionis Pharmaceuticals (IONS) announced that it has entered into a license agreement under which Sobi received exclusive rights in countries ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered into a license agreement under which Sobi® ...

Theratechnologies Inc.’s THTX share price has surged by 20.78%, which has investors questioning if this is right time to sell ...

Arrowhead Pharmaceuticals, Inc. shines with 19 clinical programs, strategic partnerships, and promising RNAi data. Click for ...

The company secured a $280 million upfront payment from a partnership with Ono Pharmaceuticals. Ongoing Phase III trials for olezarsen aim to demonstrate significant triglyceride lowering. WAYNEUWA ...

Ionis Pharma's Tryngolza (olezarsen) has become the first FDA-approved drug therapy for adults with rare disease familial chylomicronaemia syndrome. Patients with the rare disease familial ...

All figures are in U.S. dollars unless otherwise stated. Lévesque added, “The addition of olezarsen and donidalorsen in Canada are expected to drive long-term growth over and above our foundational ...